Does Rallies show Form 4 insider transactions for EVO?

Yes. Rallies tracks EVO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EVO. It does not provide personalized investment advice.

EVO (Evotec SE American Depositary Shares) Stock Analysis - Insider Trades

Evotec SE American Depositary Shares (EVO) is a publicly traded Healthcare sector company. As of May 21, 2026, EVO trades at $2.89 with a market cap of $973.22M and a P/E ratio of 0.00. EVO moved +2.70% today. Year to date, EVO is -10.97%; over the trailing twelve months it is -30.22%. Its 52-week range spans $2.31 to $5.64. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces EVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EVO stock inside the company?

Recent EVO insider activity includes Abood Thomas J. bought 120.26K, Yeros John Peter bought 50.00K, BANK OF AMERICA CORP /DE/ bought 100, BANK OF AMERICA CORP /DE/ bought 200, and BANK OF AMERICA CORP /DE/ bought 92. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EVO Key Metrics

Key financial metrics for EVO
Metric	Value
Price	$2.89
Market Cap	$973.22M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.07%
52-Week High	$5.64
52-Week Low	$2.31
Volume	789
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent EVO Insider Trades

Abood Thomas J. bought 120.26K (~$300.66K) on Apr 16, 2018.
Yeros John Peter bought 50.00K (~$150.00K) on Apr 16, 2018.
BANK OF AMERICA CORP /DE/ bought 100 (~$1.28K) on Oct 18, 2011.
BANK OF AMERICA CORP /DE/ bought 200 (~$2.56K) on Oct 18, 2011.
BANK OF AMERICA CORP /DE/ bought 92 (~$1.18K) on Oct 18, 2011.

Latest EVO News

Evotec Places €116.1M Convertible Bonds Due 2033 at 2.625% Interest — May 12, 2026
Evotec Secures Gates Grants to Finance $9.9M TB Pipeline Expansion — Apr 30, 2026
Evotec Names 20-Year Life Sciences Executive Dr. Ingrid Müller as COO to Lead Horizon Initiative — Apr 15, 2026
Evotec Cuts 800 Jobs, Sees 1.1% Revenue Drop and €75M Cost Savings Plan — Apr 8, 2026
Evotec Subsidiary Secures up to $10 Million BARDA Award for Ebola Antibody Manufacturing — Mar 23, 2026

EVO Analyst Consensus

3 analysts cover EVO: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.

Common questions about EVO

Who is trading EVO stock inside the company?: Recent EVO insider activity includes Abood Thomas J. bought 120.26K, Yeros John Peter bought 50.00K, BANK OF AMERICA CORP /DE/ bought 100, BANK OF AMERICA CORP /DE/ bought 200, and BANK OF AMERICA CORP /DE/ bought 92. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EVO?: Yes. Rallies tracks EVO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EVO. It does not provide personalized investment advice.